Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J DeAngelo

Showing results (61-70 of 320) with videos related to

Pageof 32
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2022
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialMatthias Stelljes, Anjali S Advani, Daniel J DeAngelo, et al.
British Journal of Haematology|March 21, 2022
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemiaYannis K Valtis, Andrew E Place, Lewis B Silverman, et al.
Journal of Clinical Pathology|March 29, 2018
Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary diseaseAlissa Keegan, Karry Charest, Ryan Schmidt, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemiaMarcella M Alsan, Nicolas C Issa, Sarah P Hammond, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2015
Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemiaOlga K Weinberg, Olga Pozdnyakova, Federico Campigotto, et al.
American Journal of Hematology|November 2, 2012
An extreme example of focal bone marrow involvement in acute myeloid leukemiaCharlotte K Brierley, Elizabeth A Morgan, Julian R Sprague, et al.
Blood|October 22, 2003
Fatal hepatic necrosis following imatinib mesylate therapyNancy U Lin, Stefanie Sarantopoulos, James R Stone, et al.
Journal of Oncology Practice|August 15, 2013
Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical centerBrett E Glotzbecker, Deborah S Yolin-Raley, Daniel J DeAngelo, et al.
Blood Reviews|February 22, 2023
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDSStacey M Frumm, Shai Shimony, Richard M Stone, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Pageof 32

Showing results (61-70 of 320) with videos related to

Sort By:
Pageof 32
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2022
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialMatthias Stelljes, Anjali S Advani, Daniel J DeAngelo, et al.
British Journal of Haematology|March 21, 2022
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemiaYannis K Valtis, Andrew E Place, Lewis B Silverman, et al.
Journal of Clinical Pathology|March 29, 2018
Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary diseaseAlissa Keegan, Karry Charest, Ryan Schmidt, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemiaMarcella M Alsan, Nicolas C Issa, Sarah P Hammond, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2015
Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemiaOlga K Weinberg, Olga Pozdnyakova, Federico Campigotto, et al.
American Journal of Hematology|November 2, 2012
An extreme example of focal bone marrow involvement in acute myeloid leukemiaCharlotte K Brierley, Elizabeth A Morgan, Julian R Sprague, et al.
Blood|October 22, 2003
Fatal hepatic necrosis following imatinib mesylate therapyNancy U Lin, Stefanie Sarantopoulos, James R Stone, et al.
Journal of Oncology Practice|August 15, 2013
Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical centerBrett E Glotzbecker, Deborah S Yolin-Raley, Daniel J DeAngelo, et al.
Blood Reviews|February 22, 2023
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDSStacey M Frumm, Shai Shimony, Richard M Stone, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Pageof 32